Blinatumomab for MRD-Positive B-Cell Precursor ALL: An 18-Month Follow-up

Slideset - Patients with complete MRD response after blinatumomab treatment had prolonged OS, RFS, and DoR vs those with an incomplete MRD response.

Source: Clinical Care Options Leukemia - December 14, 2015 Category: Hematology Source Type: research